Killing two kinase families with one stone

被引：29

作者：

Bilanges, Benoit ^{[1
]}

Torbett, Neil ^{[1
,2
]}

Vanhaesebroeck, Bart

机构：

[1] Barts & London Queen Marys Sch Med & Dent, Inst Canc, Ctr Cell Signalling, London EC1M 6BQ, England

[2] Piramed Pharma, Slough SL1 4NL, Berks, England

来源：

NATURE CHEMICAL BIOLOGY | 2008年 / 4卷 / 11期

基金：

英国医学研究理事会;

关键词：

D O I：

10.1038/nchembio1108-648

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 [生物化学与分子生物学]; 081704 [应用化学];

摘要：

Multitargeted protein kinase inhibitors have shown great promise in cancer therapy, but the selectivity profiles of these compounds have largely relied on serendipity or 'off-target' activities rather than rational drug design. Purposefully designed compounds with activity against multiple target kinases bring us a step closer to personalized medicine.

引用

页码：648 / 649

页数：2

共 12 条

[1]

Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases [J].

Apsel, Beth ;

Blair, Jimmy A. ;

Gonzalez, Beatriz ;

Nazif, Tamim M. ;

Feldman, Morri E. ;

Aizenstein, Brian ;

Hoffman, Randy ;

Williams, Roger L. ;

Shokat, Kevan M. ;

Knight, Zachary A. .

NATURE CHEMICAL BIOLOGY, 2008, 4 (11) :691-699

[2]

The selectivity of protein kinase inhibitors: a further update [J].

Bain, Jenny ;

Plater, Lorna ;

Elliott, Matt ;

Shpiro, Natalia ;

Hastie, C. James ;

Mclauchlan, Hilary ;

Klevernic, Iva ;

Arthur, J. Simon C. ;

Alessi, Dario R. ;

Cohen, Philip .

BIOCHEMICAL JOURNAL, 2007, 408 :297-315

[3]

A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma [J].

Fan, Qi-Wen ;

Knight, Zachary A. ;

Goldenberg, David D. ;

Yu, Wei ;

Mostov, Keith E. ;

Stokoe, David ;

Shokat, Kevan M. ;

Weiss, William A. .

CANCER CELL, 2006, 9 (05) :341-349

[4]

Synthesis and biological evaluation of pyrido[3′,2':4,5]furo [3,2-d]pyrimidine derivatives as novel PI3 kinase p110α inhibitors [J].

Hayakawa, Masahiko ;

Kaizawa, Hiroyuki ;

Moritomo, Hiroyuki ;

Koizumi, Tomonobu ;

Ohishi, Takahide ;

Yamano, Mayumi ;

Okada, Minoru ;

Ohta, Mitsuaki ;

Tsukamoto, Shin-ichi ;

Raynaud, Florence I. ;

Workman, Paul ;

Waterfield, Michael D. ;

Parker, Peter .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (09) :2438-2442

[5]

Features of selective kinase inhibitors [J].

Knight, ZA ;

Shokat, KM .

CHEMISTRY & BIOLOGY, 2005, 12 (06) :621-637

[6]

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity [J].

Maira, Sauveur-Michel ;

Stauffer, Frederic ;

Brueggen, Josef ;

Furet, Pascal ;

Schnell, Christian ;

Fritsch, Christine ;

Brachmann, Saskia ;

Chene, Patrick ;

De Pover, Alain ;

Schoemaker, Kevin ;

Fabbro, Doriano ;

Gabriel, Daniela ;

Simonen, Marjo ;

Murphy, Leon ;

Finan, Peter ;

Sellers, William ;

Garcia-Echeverria, Carlos .

MOLECULAR CANCER THERAPEUTICS, 2008, 7 (07) :1851-1863

[7]

The protein kinase complement of the human genome [J].

Manning, G ;

Whyte, DB ;

Martinez, R ;

Hunter, T ;

Sudarsanam, S .

SCIENCE, 2002, 298 (5600) :1912-+

[8]

Targeting phosphoinositide 3-kinase - Moving towards therapy [J].

Marone, Romina ;

Cmijanovic, Vladimir ;

Giese, Bemd ;

Wymann, Matthias P. .

BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS, 2008, 1784 (01) :159-185

[9]

Petrelli A, 2008, CURR MED CHEM, V15, P422

[10]

Flying under the radar:: the new wave of BCR-ABL inhibitors [J].

Quintas-Cardama, Alfonso ;

Kantarjian, Hagop ;

Cortes, Jorge .

NATURE REVIEWS DRUG DISCOVERY, 2007, 6 (10) :834-848

← 1 2 →